Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast ...

NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time ...

ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx) a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), recognizes the ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score®test: ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...